EGFR and non-small cell lung carcinoma: In the solid tumor space, adjuvant therapy with osimertinib targeting activating mutations in epidermal growth factor receptor (EGFR) in patients with completely resected, EGFR-mutated non-small cell lung cancer [43] is another example of the successful targeting of molecular MRD that improves survival.